PACIRA BIOSCIENCES, INC. Revenues
PACIRA BIOSCIENCES, INC. (PCRX) reported Revenues of $541.53 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Income Statement › Revenue
us-gaap:Revenues · last filed 2022-02-28
- PACIRA BIOSCIENCES, INC. revenues for the quarter ending 2020-12-31 was $130.97M, a 6.98% increase year-over-year.
- PACIRA BIOSCIENCES, INC. revenues for the quarter ending 2020-09-30 was $117.48M, a 12.23% increase year-over-year.
- PACIRA BIOSCIENCES, INC. revenues for the quarter ending 2020-06-30 was $75.50M, a 26.41% decline year-over-year.
- PACIRA BIOSCIENCES, INC. revenues for the quarter ending 2020-03-31 was $105.68M, a 15.74% increase year-over-year.
- PACIRA BIOSCIENCES, INC. revenues for fiscal 2021 was $541.53M, a 26.04% increase from fiscal 2020.
- PACIRA BIOSCIENCES, INC. revenues for fiscal 2020 was $429.65M, a 2.05% increase from fiscal 2019.
- PACIRA BIOSCIENCES, INC. revenues for fiscal 2019 was $421.03M, a 24.83% increase from fiscal 2018.
- PACIRA BIOSCIENCES, INC. revenues for fiscal 2018 was $337.28M, a 17.67% increase from fiscal 2017.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|---|
| 2021-12-31 | $541.53M 10-K · filed 2022-02-28 | ||||
| 2020-12-31 | $130.97M 10-K · filed 2021-03-01 | $248.46M derived: sum of 2 quarters · filed 2021-03-01 | $323.96M derived: sum of 3 quarters · filed 2021-03-01 | $429.65M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $117.48M 10-K · filed 2021-03-01 | $192.99M derived: sum of 2 quarters · filed 2021-03-01 | $298.67M derived: sum of 3 quarters · filed 2021-03-01 | $421.10M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2020-06-30 | $75.50M 10-K · filed 2021-03-01 | $181.19M derived: sum of 2 quarters · filed 2021-03-01 | $303.61M derived: sum of 3 quarters · filed 2021-03-01 | $408.30M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2020-03-31 | $105.68M 10-K · filed 2021-03-01 | $228.11M derived: sum of 2 quarters · filed 2021-03-01 | $332.79M derived: sum of 3 quarters · filed 2021-03-01 | $435.40M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-12-31 | $122.42M 10-K · filed 2021-03-01 | $227.11M derived: sum of 2 quarters · filed 2021-03-01 | $329.71M derived: sum of 3 quarters · filed 2021-03-01 | $421.03M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $104.69M 10-K · filed 2021-03-01 | $207.29M derived: sum of 2 quarters · filed 2021-03-01 | $298.60M 10-Q · filed 2019-11-08 | $393.72M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-06-30 | $102.60M 10-K · filed 2021-03-01 | $193.92M 10-Q · filed 2019-08-08 | $289.03M derived: sum of 3 quarters · filed 2021-03-01 | $372.48M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-03-31 | $91.31M 10-K · filed 2021-03-01 | $186.43M derived: sum of 2 quarters · filed 2021-03-01 | $269.88M derived: sum of 3 quarters · filed 2021-03-01 | $353.98M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2018-12-31 | $95.11M 10-K · filed 2020-02-21 | $178.56M derived: sum of 2 quarters · filed 2020-02-21 | $262.67M derived: sum of 3 quarters · filed 2020-02-21 | $337.28M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $83.45M 10-K · filed 2020-02-21 | $167.56M derived: sum of 2 quarters · filed 2020-02-21 | $242.16M 10-Q · filed 2019-11-08 | $321.24M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-06-30 | $84.11M 10-K · filed 2020-02-21 | $158.71M 10-Q · filed 2019-08-08 | $237.79M derived: sum of 3 quarters · filed 2020-02-21 | $305.13M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2018-03-31 | $74.61M 10-K · filed 2020-02-21 | $153.69M derived: sum of 2 quarters · filed 2020-02-21 | $221.02M derived: sum of 3 quarters · filed 2020-02-21 | $291.95M derived: sum of 4 quarters · filed 2020-02-21 | |
| 2017-12-31 | $79.08M 10-K · filed 2019-02-28 | $146.41M derived: sum of 2 quarters · filed 2019-02-28 | $217.35M derived: sum of 3 quarters · filed 2019-02-28 | $286.63M 10-K · filed 2020-02-21 | |
| 2017-09-30 | $67.33M 10-K · filed 2019-02-28 | $138.27M derived: sum of 2 quarters · filed 2019-02-28 | $207.55M 10-Q · filed 2018-11-01 | $280.45M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-06-30 | $70.93M 10-K · filed 2019-02-28 | $140.22M 10-Q · filed 2018-08-02 | $213.12M derived: sum of 3 quarters · filed 2019-02-28 | $281.47M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2017-03-31 | $69.28M 10-K · filed 2019-02-28 | $142.19M derived: sum of 2 quarters · filed 2019-02-28 | $210.54M derived: sum of 3 quarters · filed 2019-02-28 | $280.18M derived: sum of 4 quarters · filed 2019-02-28 | |
| 2016-12-31 | $72.90M 10-K · filed 2018-02-28 | $141.26M derived: sum of 2 quarters · filed 2018-02-28 | $210.90M derived: sum of 3 quarters · filed 2018-02-28 | $276.37M 10-K · filed 2019-02-28 | |
| 2016-09-30 | $68.36M 10-K · filed 2018-02-28 | $138.00M derived: sum of 2 quarters · filed 2018-02-28 | $203.47M 10-Q · filed 2017-11-08 | $272.79M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2016-06-30 | $69.64M 10-K · filed 2018-02-28 | $135.11M 10-Q · filed 2017-08-02 | $204.43M derived: sum of 3 quarters · filed 2018-02-28 | $266.65M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2016-03-31 | $65.47M 10-K · filed 2018-02-28 | $134.79M derived: sum of 2 quarters · filed 2018-02-28 | $197.01M derived: sum of 3 quarters · filed 2018-02-28 | $256.15M derived: sum of 4 quarters · filed 2018-02-28 | |
| 2015-12-31 | $69.32M 10-K · filed 2017-03-01 | $131.53M derived: sum of 2 quarters · filed 2017-03-01 | $190.68M derived: sum of 3 quarters · filed 2017-03-01 | $249.00M 10-K · filed 2018-02-28 | |
| 2015-09-30 | $62.21M 10-K · filed 2017-03-01 | $121.36M derived: sum of 2 quarters · filed 2017-03-01 | $179.68M 10-Q · filed 2016-11-02 | $377.35M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | $59.15M 10-K · filed 2017-03-01 | $117.46M 10-Q · filed 2016-08-04 | $315.13M derived: sum of 3 quarters · filed 2017-03-01 | $367.18M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | $58.32M 10-K · filed 2017-03-01 | $255.98M derived: sum of 2 quarters · filed 2017-03-01 | $308.03M derived: sum of 3 quarters · filed 2017-03-01 | $355.20M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | $197.67M 10-K · filed 2017-03-01 | $61.79M 10-K · filed 2015-02-24 | $249.72M derived: sum of 2 quarters · filed 2017-03-01 | $296.88M derived: sum of 3 quarters · filed 2017-03-01 | $197.67M 10-K · filed 2016-02-25 |
| 2014-09-30 | $52.05M 10-K · filed 2016-02-25 | $99.21M derived: sum of 2 quarters · filed 2016-02-25 | $135.88M 10-Q · filed 2015-10-27 | $169.44M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-06-30 | $47.16M 10-K · filed 2016-02-25 | $83.83M 10-Q · filed 2015-07-30 | $117.39M derived: sum of 3 quarters · filed 2016-02-25 | $140.65M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2014-03-31 | $36.66M 10-K · filed 2016-02-25 | $70.23M derived: sum of 2 quarters · filed 2016-02-25 | $93.48M derived: sum of 3 quarters · filed 2016-02-25 | $110.63M derived: sum of 4 quarters · filed 2016-02-25 | |
| 2013-12-31 | $33.56M 10-K · filed 2015-02-24 | $56.82M derived: sum of 2 quarters · filed 2015-02-24 | $73.96M derived: sum of 3 quarters · filed 2015-02-24 | $85.55M 10-K · filed 2016-02-25 | |
| 2013-09-30 | $23.26M 10-K · filed 2015-02-24 | $40.40M derived: sum of 2 quarters · filed 2015-02-24 | $51.99M 10-Q · filed 2014-10-30 | $62.44M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-06-30 | $17.14M 10-K · filed 2015-02-24 | $28.73M 10-Q · filed 2014-07-31 | $39.18M derived: sum of 3 quarters · filed 2015-02-24 | $47.66M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2013-03-31 | $11.59M 10-K · filed 2015-02-24 | $22.04M derived: sum of 2 quarters · filed 2015-02-24 | $30.52M derived: sum of 3 quarters · filed 2015-02-24 | $42.87M derived: sum of 4 quarters · filed 2015-02-24 | |
| 2012-12-31 | $10.45M 10-K · filed 2014-02-25 | $18.94M derived: sum of 2 quarters · filed 2014-02-25 | $31.28M derived: sum of 3 quarters · filed 2014-02-25 | $39.08M 10-K · filed 2015-02-24 | |
| 2012-09-30 | $8.49M 10-K · filed 2014-02-25 | $20.83M derived: sum of 2 quarters · filed 2014-02-25 | $28.63M 10-Q · filed 2013-10-31 | $32.87M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-06-30 | $12.34M 10-K · filed 2014-02-25 | $20.15M 10-Q · filed 2013-08-06 | $24.38M derived: sum of 3 quarters · filed 2014-02-25 | $28.34M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-03-31 | $7.80M 10-K · filed 2014-02-25 | $12.04M derived: sum of 2 quarters · filed 2014-02-25 | $15.99M derived: sum of 3 quarters · filed 2014-02-25 | $19.63M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2011-12-31 | $4.23M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $8.19M derived: sum of 2 quarters · filed 2014-02-25 | $11.82M derived: sum of 3 quarters · filed 2014-02-25 | $15.69M 10-K · filed 2014-02-25 | |
| 2011-09-30 | $3.96M 10-Q · filed 2012-11-01 | $7.59M derived: sum of 2 quarters · filed 2012-11-01 | $11.46M 10-Q · filed 2012-11-01 | $13.65M derived: sum of 4 quarters · filed 2013-03-07 | |
| 2011-06-30 | $3.64M 10-Q · filed 2012-08-09 | $7.50M 10-Q · filed 2012-08-09 | $9.69M derived: sum of 3 quarters · filed 2013-03-07 | $14.22M derived: sum of 4 quarters · filed 2013-03-07 | |
| 2011-03-31 | $3.86M 10-Q · filed 2012-05-09 | $6.05M derived: sum of 2 quarters · filed 2013-03-07 | $10.59M derived: sum of 3 quarters · filed 2013-03-07 | $13.64M derived: sum of 4 quarters · filed 2013-03-07 | |
| 2010-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-07 | $6.72M derived: sum of 2 quarters · filed 2013-03-07 | $9.78M derived: sum of 3 quarters · filed 2013-03-07 | $14.56M 10-K · filed 2013-03-07 | |
| 2010-09-30 | $4.53M 10-Q · filed 2011-10-31 | $7.59M derived: sum of 2 quarters · filed 2011-10-31 | $12.37M 10-Q · filed 2011-10-31 | ||
| 2010-06-30 | $3.06M 10-Q · filed 2011-08-11 | $7.84M 10-Q · filed 2011-08-11 | |||
| 2009-12-31 | $15.01M 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |